In summary, our study demonstrated that PLOD1 is commonly highly expressed in a wide range of cancers, which is accompanied by poor clinical prognostic outcomes, with an emphasis on the fact that we confirmed the complex relationship between PLOD1 and the tumor immune microenvironment. Here, PLOD1 is linked to neoplasm.